



NYS OASAS Medical Advisory Panel (MAP) Xylazine Guidance

Xylazine, a non-opioid sedative commonly used in veterinary medicine, has become increasingly prevalent in the unregulated drug supply in the United States. While the presence of xylazine is underreported likely both in its geographic distribution and in its contribution to overdose deaths, available data indicate xylazine is widespread and impacting overdose mortality throughout the country.¹⁻³

Although found in combination with other substances, xylazine is found in the unregulated drug supply most commonly with illicitly manufactured fentanyl, which will be called “fentanyl” for the purposes of this document. Ethnographic research suggests there is an ecological connection with xylazine being added intentionally to fentanyl to potentiate the opioid’s effects.³⁻⁴ Unlike fentanyl, xylazine is diverted from veterinary sources and introduced into the unregulated drug supply, but it is unknown at what point it is introduced.⁵ Because xylazine is approved by the U.S Food and Drug Administration (FDA) for use in veterinary medicine only, it is not classified as a controlled substance under the U.S. Controlled Substances Act.

As the prevalence of xylazine has increased in the unregulated drug supply, there have been subsequent increases in the number of hospitalizations for skin wounds associated with substance use.⁶ Xylazine can cause skin wounds that are not associated with environmental factors (such as living unhoused and/or lacking access to hygiene facilities), but rather with use of the substance itself.⁷⁻⁸ These complex wounds often occur at skin sites associated with injection, but they can occur at skin sites that are not associated with injection and in individuals who don’t inject substances.⁹ Early intervention in treating xylazine-related skin wounds can prevent them from progressing into severe necrotic skin ulcerations. For more information, please see **Appendix A**.

Because of xylazine’s increasing presence in the unregulated drug supply, people who use drugs (PWUD) are interested in having the ability to test their substances for xylazine prior to using them.¹⁰ Immunoassay drug checking technology, like [fentanyl test strips](#), provide the framework and possible implementation pathway for similar xylazine testing technology within communities. Xylazine test strips have been researched, and initial findings indicate their validity and utility; they are now available commercially.¹¹⁻¹²

Surveillance and point-of-care drug checking programs also are becoming more widely available to help both communities and PWUD test local drug supplies. In New York State, the currently available data indicate xylazine is present in the unregulated drug supply and contributing to overdose deaths throughout the state.¹³ Research conducted by the New York City Department of Health and Mental Hygiene (NYC DOHMH) using gas chromatography/mass spectrometry (GC-MS) drug checking technology found that 2.2% of the 357 sampled syringes collected by NYC DOHMH through syringe services program partners were positive for xylazine in 2017.¹⁴ More recent drug checking programs piloted by the NYC DOHMH using Fourier Transform Infrared (FTIR) technology have found xylazine present exclusively in fentanyl samples. In 2021, xylazine was involved in 19% of the opioid-involved overdose deaths in NYC.¹⁵

Early History, Ethnographic Research, and Epidemiology of Xylazine

Ethnographic research, exploring cultural phenomena through qualitative interviews and real-life observation, combined with drug checking research have provided valuable insight into the experiences of people using substances with xylazine present. Early research on xylazine in the unregulated drug supply began in Puerto Rico in 2005 after local harm

reduction programs observed deep sedation and severe skin wounds within communities of PWUD.⁷ At that time, confirmatory testing using GC-MS indicated xylazine was present in 37.6% of the used syringes collected across 11 municipalities in Puerto Rico.⁷ Xylazine was found commonly with both opioids and cocaine and was prevalent especially in cattle-farming towns. However, 22% of the participants whose syringes tested positive for xylazine reported that they did not use xylazine, indicating it may have been an unknown additive in the unregulated drug supply at the time.⁷

By 2007, xylazine use in Puerto Rico during the previous 30 days had reached over 80% of the sampled population.¹⁶ Ethnographic research from that time found that PWUD were aware of xylazine's presence in the unregulated drug supply and had used the substance both knowingly and unknowingly.^{8,16} This early research pointed to recognizable signs of xylazine based on the substance's sedative effect, taste, dark brown color, and strong odor. Skin wounds were the primary identified health concern, but the research also described the need for clinical recognition and support for xylazine withdrawal and chronic xylazine use.^{8,16}

In 2006, xylazine began appearing in medical examiner's reports in Philadelphia, making it the first city in the contiguous United States to report xylazine use.¹⁷ Although it wasn't highly prevalent in the medical examiner's reports initially, as xylazine's presence as an additive in the unregulated drug supply began to increase, there were subsequent increases in xylazine-involved overdose deaths.^{3,18} By 2021, xylazine had become the most common adulterant in Philadelphia's unregulated drug supply with 91% of samples sold as "dope" containing xylazine.¹⁹⁻²⁰ Ethnographic research indicated that by that time, PWUD in Philadelphia largely were aware of xylazine's presence in the unregulated drug supply and had mixed preferences for using the substance or avoiding it.³

Since then, xylazine has spread within the Northeast and continued westward and southward.^{3,21} U.S Drug Enforcement Administration (DEA) forensic laboratory testing showed significant increases in the presence of xylazine across all geographic regions in the United States between 2020 and 2021.²² While the Northeast had the highest total of xylazine-positive samples, the largest percentage increases were found in the South (193% increase) and the West (112% increase).²² The most recent available data from April 2021 through March 2022 found xylazine-positive samples in 25 of the 39 states where xylazine toxicology testing was ordered in primary care settings, indicating that xylazine has been incorporated widely into the unregulated drug supply throughout the United States.¹

Xylazine-Involved Overdose Deaths

Xylazine's presence in the unregulated drug supply, and its contribution to overdose deaths, is widespread and increasing.³ Xylazine is an alpha-2 adrenergic agonist that causes profound sedation and central nervous system (CNS) depression. This can contribute to a blunted response to airway occlusion much like the effects from other sedatives such as benzodiazepines and barbiturates. Because of xylazine's co-occurrence with fentanyl, the sedation that it causes has synergistic effects with the respiratory depression caused by opioids, contributing to increases in overdose mortality.²³

Xylazine likely is highly underrecognized in most overdose situations and because this substance is not an opioid, xylazine overdose is not responsive to naloxone. Naloxone has become the standard, and often the only, response to overdoses. However, most overdoses involve multiple substances, making polysubstance overdose recognition and response an important strategy to reduce overdose deaths.²⁴⁻²⁵ Xylazine often is mixed in with fentanyl, therefore naloxone administration still is the first recommended step in responding to an overdose; however, it should be followed by other lifesaving interventions such as rescue breathing. See **Appendix A** for more information on xylazine overdose recognition and response.

Because drug checking is not available in most jurisdictions, and xylazine is not included routinely on toxicology tests in health care settings, much of the available data on xylazine is from postmortem forensic testing of overdose deaths. The existing research indicates that almost all overdose deaths that involved xylazine also involved fentanyl.^{3,18,25} In 2019,

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

xylazine was involved in 31% of the opioid overdose deaths in Philadelphia, a 29% increase from 2010.¹⁸ Between 2019 and 2020, xylazine-involved overdose deaths in Connecticut increased from 5.8% to 11.4%,²⁵ and this increase continued into 2021.²⁶ All but one of these xylazine-involved overdose deaths were positive for fentanyl.²⁵ In 2021, 12.2% of the fentanyl-related deaths in Cook County, Illinois involved xylazine.²⁷

Nationally, xylazine was present in 1.8% of all overdose deaths in 2019 with fentanyl present in over 98% of xylazine-involved overdose deaths.² Provisional data from the U.S. Centers for Disease Control and Prevention (CDC) indicate xylazine was present in 5.6% of opioid-involved overdose deaths in 2022.²⁸ This has prompted national attention to increase the awareness about xylazine among PWUD, substance use disorder treatment and harm reduction providers, law enforcement, and the wider medical community and to align stakeholders for the development of best practices to address xylazine.^{9,29-31}

Future Considerations

The actual prevalence of xylazine in the unregulated drug supply remains unknown because it is not tested for widely in point-of-care or surveillance drug checking. Further, the medical establishment is often unaware of xylazine use among their patients because it is not a routine element in formal urine toxicology tests. While xylazine can be detected in post-mortem testing, it may not be included routinely on the death certificate.⁴ However, the available data indicate xylazine is widespread, increasing in prevalence, and contributing significantly to overdose mortality.

There is a need for comparative ethnographic research in geographical locations outside of Puerto Rico and Philadelphia to better understand the subjective experiences of people who are using substances with xylazine present.⁴ Additionally, to create clinical guidelines for the treatment of xylazine wounds, more research is needed on the pathophysiology of wounds associated with xylazine use. Lastly, research on the effects of physiological dependence and withdrawal from xylazine is needed to inform the development of evidence-based management of xylazine withdrawal and the treatment for xylazine use disorder.

Considering the prevalence and lethality of xylazine in the unregulated drug supply, it is important to increase the overall awareness of xylazine within communities of PWUD and among health care providers.³²⁻³³ Additionally, it is important to share information based on the existing best practices for: (1) harm reduction strategies for xylazine, (2) preventing and addressing xylazine-related skin wounds, (3) adapting overdose recognition and response to include xylazine and other sedatives added to the unregulated drug supply, and (4) clinically recognizing xylazine use and providing supportive care. See **Appendix A** for more detail on these nascent best practices. For more information on xylazine-specific harm reduction, safer injection practices, and overdose recognition and response best practices, please visit the [National Harm Reduction Coalition](#), [Substance Use Philadelphia](#), [testRI](#), and [NYS Department of Health](#). See **Appendix B** for frequently asked questions about xylazine.

Appendix A: Nascent Best Practices for Xylazine

1. Harm Reduction Strategies for Xylazine

Harm Reduction strategies for people who may be using xylazine need to be tailored to address the profound sedating effects that occur from this substance, especially in the first 20-30 minutes after use.^{4,34-35} When using substances that contain xylazine, a person can be immobilized for hours,³⁶⁻³⁷ putting them at risk for physical and sexual assault, and physical health complications such as compartment syndrome, pressure ulcers, and blood clots. Because of these potentially life-threatening risks, in addition to existing harm reduction practices, there are specific strategies to support persons who use substances that may contain xylazine.

Xylazine-focused harm reduction strategies:^{35,38}

- Have someone with you when using or use the [Never Use Alone](#) Hotline (800-484-3731)

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

- Start low and go slow
- Try to avoid mixing substances
- Test your substances
 - Use [fentanyl test strips](#) to test substances for the presence of fentanyl prior to using them
 - Use [xylazine test strips](#) to test substances for the presence of xylazine prior to using them
- Since the persons who are using substances may become deeply sedated up to 8 hours:³⁶⁻³⁷
 - Try to use in a safe location, with belongings securely stored
 - Try to be in a comfortable seated position
 - It is important to be in a position that doesn't cut off circulation to the arms or legs
 - If injecting substances, use a flexible tourniquet that can be removed easily
 - Individuals deeply sedated who cannot move themselves easily should be moved (repositioned) every 2 hours:
 - Roll the individual to the opposite side
 - Smooth out the skin
 - Gently massage/rub areas that appear red or swollen
 - Keep skin as clean as possible, and flex (bend) the joints
 - When the person awakens, exercise the limbs to improve the circulation and prevent blood clots
 - Monitor for signs of a blood clot over the next 48 hours or more
 - Signs of a blood clot usually include new-onset redness, swelling and/or pain in one lower extremity but may be asymptomatic and have no visible abnormalities
- Connect PWUD with a drug checking program so they can be aware of the substances present in the unregulated drug supply in their community, including xylazine
 - Surveillance drug checking programs are available at some [Syringe Services Programs](#) (SSPs) and [Drug User Health Hubs](#) across the state through the NYS Department of Health and NYC Department of Health and Mental Hygiene (DOHMH)
 - The NYC DOHMH recently launched a point-of-care drug checking pilot using FTIR machines at the City's two overdose prevention centers, operated by On Point NYC
 - The NYS Office of Addiction Services and Supports (OASAS) soon will be piloting in-community Outreach and Engagement Services point-of-care drug checking programs using dual (Raman and Near-Infrared spectra) spectrometer technologies
- Learn how to perform rescue breathing and keep naloxone nearby so someone can administer it to persons who are using substances if they experience an overdose
 - In the event of a suspected overdose, Emergency Medical Services (EMS) should be activated (e.g., call 911)
 - Xylazine most frequently is mixed in with fentanyl
 - Naloxone will reverse an opioid-related overdose and should be administered first, followed by rescue breathing
 - Once the first dose of naloxone is administered, the responder should wait two minutes before giving an additional naloxone dose
 - Because xylazine is not an opioid, rescue breathing is a critical part of xylazine-involved overdose response
 - Include face shields in naloxone kits to perform mouth-to-mouth resuscitation more safely
 - To open the airway, maneuvers such as a head tilt and chin lift may be necessary
 - Use an oral or nasal airway, bag valve mask (e.g., Ambu bag), supplemental oxygen, and pulse oximetry, if available


2. Preventing, Recognizing, and Addressing Xylazine-Related Skin Wounds

Preventing Xylazine Wounds

Safer injection education and wound care are important for persons who use substances with or without xylazine present. There is, however, an increased risk for developing skin wounds when injecting substances that contain xylazine. See below for general safer injecting practices, including specific strategies to stay safer when using substances that may contain xylazine. For more information on safer injection, please visit the [National Harm Reduction Coalition](#) (NHRC), [NASTAD](#), and [Bevel Up](#).

See **Figure 1** for xylazine safer injection practices found in the [Xylazine in the Drug Supply](#) guide developed by NHRC based on advice from people who use/have used xylazine.³⁸ Because xylazine is an emerging and novel substance, these are nascent practices shared within communities of PWUD to reduce the harms from xylazine. It is possible that cooking a substance twice to dissolve all chunks may ensure that there is an even distribution to prevent one specific part of the skin and/or body from receiving a disproportionate amount of the substance, thereby potentially reducing the risk for developing wounds.

Figure 1. Xylazine Safer Injection³⁸



In addition to the risk of developing injection-related skin wounds, insufflation of substances that contain xylazine can contribute to damage inside the nose resulting in blood and tissue discharge from the nostril.³⁹ Engagement around trying other ways to use substances besides injection, such as ingestion, rectal insertion (booty bumping), smoking, or insufflation with an atomizer, may help reduce some of the risk for developing xylazine wounds and/or nasal damage.³⁸⁻³⁹ However, xylazine wounds can occur at skin sites that are not associated with injection and in individuals who don't inject substances;⁹ therefore, xylazine skin wounds still may occur despite using these alternative routes of administration. See the **Recognizing and Addressing Xylazine Wounds** section for more information on caring for xylazine wounds.

General and xylazine-specific safer injection practices:⁴⁰⁻⁴²


- Access to safer injection kits that include^{39,43-44}
 - Clean syringes
 - It is important that persons who inject substances have access to a new syringe every time they inject (**see Figure 2**)
 - Cookers (aluminum caps)
 - It is important that person who inject substances have access to their own cooker and do not share cookers
 - Cottons (filters)

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

- It is important that person who inject substances have access to their own cottons and do not share cottons
- [Fentanyl test strips](#)
- [Xylazine test strips](#)
- Alcohol pads
- Sterile water vials
- Gauze
- Soap or hand sanitizer (to keep hands clean)
- Tourniquets
- Keep the injection site clean and dry
 - Before injecting, clean the site with an alcohol pad
 - When using an alcohol pad, clean the site by wiping in the same direction
 - Avoid picking at the skin around the site of injection or other areas of the body
- Do a test shot and wait to see the effects
- Rotate injection sites frequently
 - Avoid injecting at the site of a wound or infection
- Cut back on or stop xylazine use (if feasible)
- Visit your local harm reduction program to access safer injection education and supplies
 - [Syringe Services Programs](#)
 - [Drug User Health Hubs](#)

Figure 2. Needle Tip Wear Over Time⁴²



Recognizing and Addressing Xylazine Wounds

Xylazine wounds are underrecognized by medical providers and have an unknown etiology. These wounds can occur at skin sites that are not associated with injection and in individuals who don't inject substances.⁹ Xylazine wounds often begin as a small purple or white spot with an oddly shaped red or purple border that can resemble a bruise.³⁹ These wounds initially appear innocuous, and often are overlooked in the early stages, but they will become more severe if left untreated. There are three basic tenets of wound care: keep the wound moist, stable in temperature, and covered.^{40,41}

If a wound begins to develop³⁹⁻⁴²

- Wash hands before tending to wounds
- Clean:
 - When possible, keep the wound clean with soap and sterile water
 - Other cleaning agents include:
 - Chlorhexidine solution
 - Dakin's half-strength solution (buffering agent/antiseptic)
 - 1% acetic acid (main component of vinegar)
 - BZK antiseptic wipes
 - It is recommended to avoid cleaning wounds with alcohol, hydrogen peroxide, or hand sanitizer because they will dry out the wound
- Dress:
 - Apply ointment to the affected areas using a Q-Tip, gauze, or with a gloved or clean hand.
 - Some recommended ointments based on nascent best practices shared by wound care street outreach teams include:
 - A&D ointment
 - Petroleum or petrolatum jelly
 - Medical honey, such as manuka or Medi-honey⁴⁵
 - Honey has emerged as a promising wound care treatment because of its antibacterial and wound healing properties⁴⁷
 - Xeroform
 - Adaptec
 - Try to avoid putting ointment on intact or healthy skin
- Absorb:
 - Cover the wound with an absorbent pad and a non-adherent dressing to absorb secretions from the wound^{39,40} Recommended pads:
 - ABD pads
 - Sponge
 - Gauze
 - Avoid wrapping the wound too tightly or too loosely
 - Change dressing daily, if possible
- Secure and Protect:
 - Securely wrap the area to keep the dressing in place and protect the wound from dirt and moisture.
 - Recommended wraps:
 - Coban
 - Gauze wrap (kerlix)
- Continue to check the wound for possible infection
 - While xylazine wounds are not themselves infectious, they can become infected secondarily with bacteria, particularly when the person picks at the skin around the wound or other areas of the body
 - To prevent a secondary bacterial infection, it is important to keep hands clean with soap and water when cleaning a wound
 - Symptoms of a secondary bacterial infection include:
 - Redness
 - Swelling
 - Worsening pain
 - Fever

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

- Tiredness
- Increased drainage (pus or fluid)
- Drainage that is yellow/tan/green
- Odor/smell from the wound
- Wound feels hot to the touch
- Wound increases in size with a black, yellow, or tan color
- Seek medical attention if any symptoms of infection begin to develop
 - Debridement in the emergency department, an outpatient setting, or a surgical setting may be required to treat effectively xylazine wounds that have progressed
 - If left untreated, xylazine-caused wounds may require significant treatment, including skin grafting or amputation as a last resort

Motivational interviewing to address self-care is important when engaging around wound care.^{39,40} It is also important that wound care strategies are individualized to the needs, and environment, of the person who will be caring for their wounds.⁴⁶ More information on xylazine-caused wound care can be found at [NASTAD](#) and [The Harm Reduction Nurses Association](#).

3. Xylazine-Involved Overdose Recognition and Response

Because xylazine is so often found mixed in with fentanyl (an opioid) in the unregulated drug supply, when responding to an overdose, assume an opioid is involved and administer naloxone. Once administered, the responder should wait two minutes before giving an additional naloxone dose. However, if an individual is not responding to 1-2 doses of naloxone, suspect that it is a polysubstance overdose with possible xylazine involvement.⁴⁸ See **Figure 3** for a fact sheet on recognizing and responding to polysubstance overdoses.

If responding to a known or suspected xylazine-involved overdose, the response should include rescue breathing, placing the person in the recovery position, and ensuring an open airway.^{44,48} Overdose reversals that have xylazine involvement may not present the same as overdose reversals without xylazine involvement.^{39,40} After administering naloxone and performing rescue breathing, a person who is experiencing an overdose from both opioids and xylazine may begin breathing again but remain sedated.^{39,40} Appropriately recognizing and responding to a polysubstance overdose also will prevent over administration of naloxone that can cause severe precipitated opioid withdrawal.

In addition to checking for breathing, check for a pulse. If there is no pulse, the recommendation is to perform chest compressions or full CPR, if trained to do so. If not trained to perform CPR, activate EMS.

Having a low threshold for activating EMS when responding to a suspected xylazine-involved overdose is recommended. When EMS respond to a suspected xylazine-involved overdose, continuous pulse oximetry and airway monitoring/control using bag valve masks (e.g., Ambu bags), oral and nasal airways, or intubation and ventilator support may be needed.⁴⁴ There currently are no medications approved for use in humans that will reverse xylazine's effects in the event of an overdose.

Figure 3. Polysubstance Overdose Recognition and Response⁴⁹

Overdose: Not just naloxone!

If someone took benzos or xylazine (*tranq/sleepdope*), naloxone may not be enough! What do you do!?!?

If they aren't breathing:


1. Try to **wake them up**
2. **CALL 911**, ask for EMS!!
3. **Use naloxone** to reverse fentanyl/opioid overdose. Give 1 or 2 doses. Naloxone takes 3-5 minutes to work!
4. While you are waiting for the naloxone, perform **rescue breathing**:
 - Take a deep breath, pinch their nose, cover their mouth with yours, blow into their lungs like blowing up a balloon
 - Two breaths to start then 1 every 5 seconds
5. **Keep checking for breathing**
 - Put your ear near their mouth and nose
 - Feel, look, listen for breathing, check for color returning
6. If they are still not breathing, **continue rescue breaths until EMS arrives**

If they are breathing, but not waking up:

There may be other drugs involved like benzos or xylazine (*tranq/sleepdope*). More naloxone won't help!

Roll them into **recovery position**:

- Roll them on their side, with one side's arm and leg straight, the other side's arm and leg bent. This position will keep them on their side so they won't choke if they vomit



4. Xylazine Clinical Recognition and Supportive Care

The effects of xylazine are similar to other alpha-2 agonists such as clonidine, dexmedetomidine, oxymetazoline, tetrahydrozoline, tizanidine, and lofexidine. Xylazine causes profound sedation, but it does not act on the imidazoline receptors, so it does not cause hypotension or bradycardia.^{5,50} Xylazine is lipophilic, diffuses widely in the body, and has good bioavailability.²³ Depending on the route of administration, xylazine takes effect in 1-2 minutes and the duration of effect lasts between 3 and 4 hours, on average, but can last up to 8 hours.³⁶⁻³⁷ See **Table 1** for clinical findings and supportive care considerations for xylazine.

Table 1. Xylazine Clinical Findings and Supportive Care Considerations³⁶⁻³⁷

Possible Clinical Findings (especially with polysubstance use)	Supportive Care Considerations
Blood pressure instability	Avoid CNS depressants
Heart rate instability	Give oxygen
Heavy sedation, unconsciousness, coma	Consider IV fluids
Respiratory depression or arrest	Consider IV atropine (no clear data to support this)
Hyperglycemia (with rebound hypoglycemia)	Ventilator assistance, possible intubation
Cardiac arrhythmias	Consider IV insulin
Miosis	Consider ECG continuous monitoring
Hyporeflexia	Consider pulse oximetry continuous monitoring
CNS depression	Consider replacement of potassium and magnesium
Enuresis (urinary incontinence)	Hemodialysis is not effective at removing xylazine due to its lipophilicity

There is an under recognition of xylazine withdrawal by clinicians that negatively impacts PWUD and their ability to receive quality care.^{32-33,50-51} While there are no current evidence-based recommendations for the management of xylazine withdrawal syndrome, it is important to recognize and sufficiently treat xylazine withdrawal symptoms. Because

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

xylazine often is mixed in with fentanyl in the unregulated drug supply, xylazine withdrawal symptoms can occur simultaneously with and appear similar to opioid withdrawal syndrome (OWS). If a person is not experiencing relief from OWS management, consider xylazine involvement and modify the treatment to address both OWS and xylazine withdrawal. See **Table 2** for the comparisons between xylazine and opioid withdrawal syndromes.

Although xylazine withdrawal is not a well-defined syndrome, non-specific anxiety is the primary symptom.^{9,19,53} Other symptoms of xylazine withdrawal can appear much like the symptoms associated with clonidine and dexmedetomidine withdrawal.⁵ There are typically no significant vital sign abnormalities or seizures associated with xylazine withdrawal. The duration of xylazine withdrawal lasts typically several days but it can be protracted, lasting for several weeks.

Table 2. Comparisons Between Xylazine and Opioid Withdrawal Syndromes

Opioid Withdrawal Syndrome ⁵⁴	Xylazine Withdrawal Syndrome ^{9,19,53}
Myalgias	Non-specific anxiety (primary symptom)
Hypertension	Hypertension
Tachycardia	Tachycardia
Diaphoresis	Diaphoresis
Tachypnea	Restlessness
Pupillary dilation	Agitation
Hyperreflexia	Irritability
Hyperthermia	
Photophobia	
Diarrhea	
Nausea/vomiting	
Insomnia	
Piloerection “goose flesh”	
Lacrimation or rhinorrhea	

People are more likely to remain in treatment for their substance use disorder, skin wounds, or other health needs if all their withdrawal symptoms are managed adequately and they are comfortable.³² Negative experiences with poorly managed or untreated withdrawal symptoms can result in future health care avoidance, later presentations of medical problems, more complicated care, and worse medical outcomes.³² Case reports suggest there are benefits to using other alpha-2 agonists like clonidine, tizanidine, and dexmedetomidine for managing xylazine withdrawal symptoms.^{5,9,19,37,53}

The Philadelphia Department of Public Health, based on the recommendations of local addiction medicine and toxicology experts, recommends considering the following medications for the inpatient management of xylazine withdrawal:¹⁹

- Clonidine (dose limited secondary to side effects of hypotension and bradycardia)
- Tizanidine (dose limited secondary to side effects of hypotension and bradycardia)
- Dexmedetomidine
- Guanfacine
- Ketamine
- Gabapentin
- Pentobarbital
- Antipsychotic medications
- Lofexidine (dose limited secondary to side effects of hypotension and bradycardia)

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

Depending on the severity of the symptoms and concomitant other withdrawal syndromes, it may be possible to manage xylazine withdrawal in medically managed/medically supervised withdrawal and stabilization programs, inpatient rehabilitation programs, or outpatient/office-based settings. It is important especially for clinicians to recognize and manage xylazine withdrawal while providing acute medical care for PWUD, such as wound care.^{32,51}

Appendix B: Frequently Asked Questions on Xylazine

Why is xylazine showing up in the unregulated drug supply?

There appears to be an ecological connection between xylazine and fentanyl in the unregulated drug supply.³ Ethnographic data describe xylazine as giving fentanyl “legs” meaning xylazine extends the duration of effect that fentanyl has. Historically, the unregulated drug supply has shifted towards more potent substances in response to the prohibition of other substances.⁵⁵ These shifts lead to greater risk for harm and overdose,⁵⁶ as currently seen with xylazine.

Are xylazine test strips available?

Xylazine test strips (XTS) recently became available commercially in the United States. Two recent studies on the validity and utility of XTS found they are effective in their sensitivity (100%), specificity (85%), and precision (91%) to detect xylazine.^{11,12}

This research determined xylazine can be detected [with the test strips](#) by diluting a small sample of the substance in water in a similar way as done with fentanyl test strips. Like [fentanyl test strips](#), there also is a risk for false positives in samples that have high concentrations of certain substances. A false positive (the measure of specificity) occurs when a test strip indicates xylazine is present in the substance when it isn't. False positives are more common when diphenhydramine, lidocaine, levamisole, MDMA (e.g., Molly or ecstasy), or methamphetamine are present in the substance.^{11,12} Future research is needed to determine the dilution instructions for using XTS to test samples with those substances present.

Presently, there are pilot studies by the NYC DOHMH, in conjunction with drug checking programs, that are exploring the implementation of XTS. XTS are now available; for more information, please visit [BTNX](#). To learn more about the research on XTS, please visit CFSRE [here](#) and [here](#).

How can I know what substances are present in the community where I live?

Drug checking programs are becoming more widely available in NYS to help both communities and PWUD test local drug supplies. Connecting PWUD with a harm reduction program that has either surveillance or point-of-care drug checking technologies available can help them stay informed about the substances that are present in the unregulated drug supply in their community.

Drug checking programs using GC-MS technology are being piloted at [Drug User Health Hubs](#) and other [Syringe Services Program](#) locations across NYS. In these pilots, a sample of the substance is sent to a central laboratory to determine the chemical composition of the contents. The results from the laboratory are available several days later; therefore, these technologies only can provide surveillance feedback regarding trends in the unregulated drug supply within a community.

Point-of-care drug checking technologies allow for a sample to be tested rapidly and the results relayed to the person who intends to use it so they can adjust their substance use accordingly. The NYC DOHMH recently launched a point-of-care drug checking pilot project using FTIR machines.⁵⁷ This drug checking pilot project has found xylazine present in fentanyl samples collected in NYC.¹⁵

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

There are also current efforts at OASAS to increase the availability of point-of-care drug checking programs to street outreach teams. Working with 16 providers throughout the state providing in-community Outreach and Engagement Services, OASAS will be piloting the use of a cutting-edge dual spectrometer. By obtaining and analyzing both Raman and Near-Infrared spectra, the devices will provide instant, real-time reporting on the identify and concentration of drug mixtures and their analogues. Using a cloud-based infrastructure, the machines will update continuously to record and adapt their inventory to the changes in the drug supply.

How do additives like xylazine impact the initiation of medications for opioid use disorder (MOUD)?

The American Society of Addiction Medicine (ASAM) is developing guidance on the initiation of buprenorphine in the setting of frequent exposure to high potency synthetic opioids. This guidance briefly will address other additives, including xylazine, in the unregulated drug supply. For now, recognizing and managing opioid and xylazine withdrawal is important when initiating MOUD and providing wound care in clinical settings.

Do xylazine wounds require hospitalization?

If detected and treated early, xylazine wounds can be managed without requiring hospitalization.^{39,40} PWUD, regardless of how they use substances, should keep an eye out for small white or purple spots that may appear on the skin. Because xylazine-induced wounds can occur in locations not associated with injection and in individuals who don't inject substances, all PWUD should have access to wound care education and supplies.

There are three main tenets to wound care: keeping the wound moist, keeping the temperature of the wound regulated, and keeping the wound covered.^{39,40} If a wound worsens or becomes infected secondarily with bacteria, it is important to seek care as soon as possible. Street outreach teams are an important resource for providing PWUD with education and supplies to prevent wounds, support and supplies for wound care, and warm handoffs to medical providers when needed. When providing wound care support, health care professionals also should monitor the person actively and treat any prolonged withdrawal symptoms that aren't relieved by medications used to manage opioid withdrawal symptoms.

Does naloxone work on xylazine?

Because xylazine is not an opioid, naloxone (an opioid receptor antagonist) will not reverse xylazine overdoses. However, because xylazine frequently is mixed in with fentanyl in the unregulated drug supply³ it is still recommended that naloxone is administered for any suspected overdose. If a person is not responding after 1-2 doses of naloxone, suspect that it is a polysubstance overdose with possible xylazine or other sedative involvement. When responding to a suspected overdose, EMS should be called. Polysubstance overdose response should include rescue breathing, placing the person in the recovery position, and ensuring an open airway.^{44,48} Administering more doses of naloxone in the event of a polysubstance overdose will not help reverse the non-opioid contributions to the overdose and may cause the person to go into severe precipitated opioid withdrawal.

References

1. Holt, AC, Schwoppe, DM, Le, K, Schrecker, JP, Heltsley, R. Widespread Distribution of Xylazine Detected Throughout the United States in Healthcare Patient Samples. *Journal of Addiction Medicine* 2023;10.1097/ADM.0000000000001132. doi: 10.1097/ADM.0000000000001132
2. Kariisa M, Patel P, Smith H, Bitting J. *Notes from the Field: Xylazine Detection and Involvement in Drug Overdose Deaths — United States, 2019*. *MMWR Morb Mortal Wkly Rep* 2021;70:1300–1302. <https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a4.htm>

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

3. Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. *Drug Alcohol Depend.* 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380
4. Dasgupta N. Office Hours: Responding to Xylazine in the Drug Supply. National Harm Reduction Coalition. April 8, 2022. Accessed April 6, 2023. <https://www.youtube.com/watch?v=7IRGePeKOMc>
5. D’Orazio J. Addiction Medicine Rounds: Toxicity of Xylazine and How It Impacts Treatment for People Who Use Drugs. Yale School of Medicine. November 22, 2022. Accessed April 6, 2023. <https://medicine.yale.edu/intmed/genmed/addictionmedicine/education/amrounds/>
6. Philadelphia Department of Public Health. Hospitalizations for Infections Related to Injection Drug Use, 2013–2018. CHART 2020; 5(1), 1-6. <https://www.phila.gov/media/20200206154343/CHART-v5e1.pdf>
7. Rodríguez N, Vargas Vidot J, Panelli J, Colón H, Ritchie B, Yamamura Y. GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. *Drug Alcohol Depend.* 2008;96(3):290-293. doi:10.1016/j.drugalcdep.2008.03.005
8. Torruella RA. Xylazine (veterinary sedative) use in Puerto Rico. *Subst Abuse Treat Prev Policy.* 2011; 6:7. Published 2011 Apr 11. doi:10.1186/1747-597X-6-7
9. U.S. Food and Drug Administration. FDA Alerts Health Care Professionals of Risks to Patients Exposed to Xylazine in Illicit Drugs. November 8, 2022. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs>
10. Reed MK, Imperato JMB, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl/heroin adulterated with the animal tranquilizer xylazine; Making a case for xylazine test strips. *Drug and Alcohol Dependence Reports.* 2022. <https://doi.org/10.1016/j.dadr.2022.100074>
11. Shuda S, Lam HY. Characterization of Xylazine Test Strips for Use in Drug Checking. The Center for Forensic Science Research & Education. October 2022. Accessed April 6, 2023. https://www.cfsre.org/images/content/reports/drug_checking/CFSRE_Xylazine_Report-Rev-1-18-23.pdf
12. The Center for Forensic Science Research & Education. Evaluation of Xylazine Test Strips (BTNX) for Drug Checking Purposes. March 22, 2023. Accessed April 6, 2023. <https://www.cfsre.org/nps-discovery/drug-checking/evaluation-of-xylazine-test-strips-btnx-for-drug-checking-purposes>
13. New York State Department of Health. New York State Department of Health Warns New Yorkers About the Prevalence of Fentanyl in Opioids, Cocaine, and other Illicit Drugs. December 9, 2022. https://www.health.ny.gov/press/releases/2022/2022-12-09_prevalence_of_fentanyl.htm
14. Fiorentin TR, Logan BK. Analytical findings in used syringes from a syringe exchange program. *Int J Drug Policy.* 2020;81:102770. doi:10.1016/j.drugpo.2020.102770
15. New York City Department of Health and Mental Hygiene. Xylazine and Fentanyl in the New York City (NYC) Drug Supply. December 27, 2022. <https://www.nyc.gov/assets/doh/downloads/pdf/han/advisory/2022/xylazine-and-fentanyl.pdf>
16. Reyes JC, Negrón JL, Colón HM, et al. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. *J Urban Health.* 2012;89(3):519-526. doi:10.1007/s11524-011-9662-6
17. Wong SC, Curtis JA, Wingert WE. Concurrent detection of heroin, fentanyl, and xylazine in seven drug-related deaths reported from the Philadelphia Medical Examiner's Office. *J Forensic Sci.* 2008;53(2):495-498. doi:10.1111/j.1556-4029.2007.00648.
18. Johnson J, Pizzicato L, Johnson C, Viner K. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019. *Inj Prev.* 2021;27(4):395-398. doi: 10.1136/injuryprev-2020-043968
19. Philadelphia Department of Public Health Commissioner’s Office. Health Alert Risks of Xylazine Use and Withdrawal in People who Use Drugs in Philadelphia. March 16, 2022. https://hip.phila.gov/document/2524/PDPH-HAN_Alert_1_Xylazine_03.16.2022.pdf/

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

20. The Center for Forensic Science Research & Education. Drug Checking Quarterly Report (Q3 2022): Philadelphia, Pennsylvania, USA. November 21, 2022. <https://www.cfsre.org/nps-discovery/drug-checking/drug-checking-q3-2022-philadelphia-pennsylvania-usa>
21. Nevada State Opioid Response. Xylazine: A Toxic Adulterant Found in Illicit Street Drugs. October 2020. <https://www.nvopioidresponse.org/wp-content/uploads/2020/10/u-public-alert-xylazine-003.pdf>
22. U.S. Department of Justice, U.S. Drug Enforcement Administration. The growing threat of xylazine and its mixture with illicit drugs. December 21, 2022. Accessed April 6, 2023. <https://www.dea.gov/documents/2022/2022-12/2022-12-21/growing-threat-xylazine-and-its-mixture-illicit-drugs>
23. Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, Martínez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature. *Forensic Sci Int.* 2014;240:1-8. doi:10.1016/j.forsciint.2014.03.015
24. Park JN, Schneider KE, Fowler D, Sherman SG, Mojtabai R, Nestadt PS. Polysubstance Overdose Deaths in the Fentanyl Era: A Latent Class Analysis. *J Addict Med.* 2022;16(1):49-55. doi:10.1097/ADM.0000000000000823
25. Thangada S, Clinton HA, Ali S, et al. *Notes from the Field: Xylazine, a Veterinary Tranquilizer, Identified as an Emerging Novel Substance in Drug Overdose Deaths — Connecticut, 2019–2020.* MMWR Morb Mortal Wkly Rep 2021;70:1303–1304. DOI: <http://dx.doi.org/10.15585/mmwr.mm7037a5>
26. Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and Overdoses: Trends, Concerns, and Recommendations. *Am J Public Health.* 2022;112(8):1212-1216. doi:10.2105/AJPH.2022.306881
27. Chhabra N, Mir M, Hua MJ, et al. Notes from the Field: Xylazine-Related Deaths — Cook County, Illinois, 2017–2021. MMWR Morb Mortal Wkly Rep 2022;71:503–504. DOI: <http://dx.doi.org/10.15585/mmwr.mm7113a3>
28. Jones C. The Drug Overdose Crisis in the U.S.: What the Latest Data Tell Us. Reagan-Udall Foundation for the FDA. March 8, 2023. Accessed April 6, 2023. https://reaganudall.org/sites/default/files/2023-03/Understanding%20Fatal%20Overdoses_Slides_Day%201.pdf
29. White House Office of National Drug Control Policy. Readout from Dr. Gupta’s Listening Session with Public Health and Safety Leaders on Xylazine and Efforts to Address Trends. December 27, 2022. <https://www.whitehouse.gov/ondcp/briefing-room/2022/12/27/readout-from-dr-guptas-listening-session-with-public-health-and-safety-leaders-on-xylazine-and-efforts-to-address-trends/>
30. National Institute on Drug Abuse. Xylazine. Accessed April 6, 2023. <https://nida.nih.gov/research-topics/xylazine>
31. Substance Abuse and Mental Health Services Administration. SAMHSA is Alerting Providers and Grantees About the Risks of Xylazine. March 27, 2023. Accessed April 6, 2023. <https://www.samhsa.gov/sites/default/files/colleague-letter-xylazine.pdf>
32. Sue K MD, PhD. Assistant Professor of Medicine General Internal Medicine. Yale School of Medicine. Clinical Expert.
33. Fiore K, Frieden J. What doctors should know about xylazine in fentanyl. *MedPage Today.* February 1, 2023. Accessed April 6, 2023. <https://www.medpagetoday.com/special-reports/features/102915>
34. Kullmann A, Sanz M, Fosgate GT, Saulez MN, Page PC, Rioja E. Effects of xylazine, romifidine, or detomidine on hematology, biochemistry, and splenic thickness in healthy horses. *Can Vet J.* 2014;55(4):334-340.
35. Zagorski C. Office Hours Part 2: Responding to Xylazine in the Drug Supply. National Harm Reduction Coalition. April 27, 2022. Accessed April 6, 2023. <https://www.youtube.com/watch?v=IGyMrOvZrWo>
36. BCCDC Harm Reduction Services. Xylazine. Towardtheheart.com. January 24, 2022. http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Statistics%20and%20Reports/Overdose/Xylazine%20HCP%2024Jan22_FINAL.pdf

37. ToxTalks. Xylazine: Overdose Cases on the Rise Blue Ridge Poison Center, University of Virginia Health. February 2022. Accessed April 6, 2023. <https://med.virginia.edu/toxicology/wp-content/uploads/sites/268/2022/02/Feb22-Xylazine.pdf>
38. National Harm Reduction Coalition. Xylazine (zie-luh-zeen). Accessed April 6, 2023. <https://harmreduction.org/issues/xylazine/>
39. Bienert J. Emerging Practices in Xylazine Wound Care. National Council for Mental Wellbeing. June 13, 2023. https://thenationalcouncil-org.zoom.us/rec/play/wh-wP-ZUysdGuXYMoXCb69uMliMaWkfmaM98wyFRmzTaACrfzD57V9CHVK4IZDHSnjfnaSAxYgABL8wW.rdp1ETrWdkvDs28z?canPlayFromShare=true&from=share_recording_detail&continueMode=true&componentName=rec-play&originRequestUrl=https%3A%2F%2Fthenationalcouncil-org.zoom.us%2Frec%2Fshare%2F-9Bt_uCy9uL3VODOy_a5tzzAzPSOB-qnwOySOEe6xjCFnBuvHFqXCWjZ58gdGgGn.8ff4G1htHQRLSQUH
40. Bienert J. Beyond the Alerts: Practical Guidance for Responding to Xylazine. National Alliance of State and Territorial AIDS Directors-NASTAD. February 21, 2023. <https://nastad.org/events/webinar-beyond-alerts-practical-guidance-responding-xylazine>
41. Opioid Response Network. Wound Care Summit. September 20, 2023.
42. Macon C, Shhipar A. xylaZINE: What is xylazine and why is it in the drug supply? October 27, 2022. *Medium*. Accessed April 6, 2023. <https://medium.com/pphc/xylazine-what-is-xylazine-and-why-is-it-in-the-drug-supply-a1a79452485c>
43. Hosey R, RN, BSN, MPH. Tranq in the supply. University of Pennsylvania School of Nursing. November 17, 2022. Accessed April 6, 2023. https://twitter.com/Becca_Hosey/status/1593277085254123520
44. Stern, S RN, MPH. Health Clinic Nurse. New York Harm Reduction Educators/OnPoint NYC. Clinical Expert.
45. Bryant K DNP, WHNP, CHSE. Associate Professor of Nursing at CUMC & Assistant Dean, Clinical Affairs and Simulation Center. Columbia School of Nursing. Clinical Expert. Personal communication February 6, 2023.
46. Hosey R. Harm Reduction Nurses Association. Xylazine effect on wounds: Why and how we care. January 12, 2023. Accessed April 6, 2023. <https://www.youtube.com/watch?v=Isaq4gsl1kA>
47. Tashkandi H. Honey in wound healing: An updated review. *Open Life Sci*. 2021;16(1):1091-1100. Published 2021 Oct 6. doi:10.1515/biol-2021-0084
48. Al-Asad A. Office Hours Part 2: Responding to Xylazine in the Drug Supply. National Harm Reduction Coalition. April 27, 2022. Accessed April 6, 2023. <https://www.youtube.com/watch?v=IGyMrOvZrWo>
49. Bell A, Dunn A. Overdose: Not just naloxone! Prevention Point Pittsburgh. January 26, 2023. Accessed April 6, 2023. <https://www.pppgh.org/>
50. Lowry JA, Brown JT. Significance of the imidazoline receptors in toxicology. *Clin Toxicol (Phila)*. 2014;52(5):454-469. doi:10.3109/15563650.2014.898770
51. Ehrman-Dupre R, Kaigh C, Salzman M, Haroz R, Peterson LK, Schmidt R. Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report. *J Addict Med*. 2022;16(5):595-598. doi:10.1097/ADM.0000000000000955
52. Bebinger M. An animal tranquilizer is making street drugs even more dangerous. *NPR*. August 5, 2022. Accessed April 6, 2023. <https://www.npr.org/sections/health-shots/2022/08/05/1114453468/animal-tranquilizer-street-drugs>
53. Rubin R. Warning About Xylazine, a Veterinary Sedative Found in Illicit Drugs. *JAMA*. 2022;328(23):2296. doi:10.1001/jama.2022.20045
54. Shah M, Huecker MR. Opioid Withdrawal. [Updated 2023 Jan 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526012/>
55. Beletsky L, Davis CS. Today's fentanyl crisis: Prohibition's Iron Law, revisited. *Int J Drug Policy*. 2017;46:156-159. doi:10.1016/j.drugpo.2017.05.050
56. Tyndall M. A safer drug supply: a pragmatic and ethical response to the overdose crisis. *CMAJ*. 2020;192(34):E986-E987. doi:10.1503/cmaj.201618

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460

57. Lewis, C. NYC launches drug checking program to spot fentanyl before people overdose. *Gothamist*. December 8, 2022. Accessed April 6, 2023. <https://gothamist.com/news/nyc-launches-drug-checking-program-to-spot-fentanyl-before-people-overdose>

501 7th Avenue | New York, New York 10018-5903 | oasas.ny.gov | 646-728-4760

1450 Western Avenue | Albany, New York 12203-3526 | oasas.ny.gov | 518-473-3460